Our treatments address the unmet needs of large patient populations
Oxular’s administration and drug-formulation technologies offer tissue-specific delivery of potent drug products to specifically address multiple pathophysiological pathways of retinal disease.
Oxular’s drug formulation technology offers treatment duration that provides up to 12-months of treatment effects from a single administration.
Oxular’s leadership is committed to developing treatments that are truly life-changing for patients suffering from sight-threatening diseases. The company is well positioned to drive its future growth as a clinical-stage retinal therapeutics development company.
Oxular is in clinical development of its lead asset, OXU-001, for the treatment of diabetic macular edema (DME). It is also developing its product pipeline for other indications, while building its team to support future clinical trials and expanded R&D activities.
Oxular’s development pipeline includes treatments for retinal diseases, such as diabetic macular edema and macular degeneration, as well as programs for rare and orphan conditions, including ocular cancers and delivery of gene therapies.
"Oxular has built an exceptional platform that has the potential to unlock the full therapeutic potential of potent molecules and significantly improve patients’ lives by providing safe, efficacious, and convenient treatment options."
Oxular Limited, Magdalen Centre, 1 Robert Robinson Avenue, Oxford OX4 4GA, UK
Limited company registered in England and Wales (Registration No. 09331313) VAT No. GB 244 5883 81
Accessibility • Privacy and cookie policy • Conditions of use • Sitemap • Contact